Yongyuan Hesheng Secures 50M CNY Angel Round for AI Biological Data

On November 4, 2026, 36Kr reported that Yongyuan Hesheng, an AI bio-data platform formally registered as Yongyuan Hesheng Technology (Shenzhen) Co., Ltd., had recently closed a 50 million RMB angel round co-led by Shunwei Capital and Yunmu Capital. The funds are slated for producing high-value datasets, expanding capacity for the company's in-house DNA synthesis technology, and further building out its data minting infrastructure.

The company positions itself as a data minting platform for the AI-plus-biology space. It offers researchers, pharma companies, and model teams an end-to-end service spanning sequence construction, functional experiments, and data curation, ultimately delivering sequence-function datasets that are AI-ready. Founder and CEO Yang Zongying explained that for AI-driven biological design teams, generating candidate sequences is only half the problem: what still needs answering experimentally is how those designs actually perform under specified conditions, and which directions should be optimized next. Yongyuan Hesheng aims to own that step, linking DNA construction, function measurement, and data curation to produce sequence-function data around each client's research question. Such data can be used to train models, evaluate them, compare candidate designs, and plan the next round of experiments. Yang also recounted that back in 2015, while studying synthetic biology at Imperial College London, he observed that despite the field's rising profile, laboratory research practices remained relatively primitive.